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The aim of this study was to assess the effects of short-term esmolol therapy on coronary artery structure and function and plasma
oxidative stress in spontaneously hypertensive rats (SHR). For this purpose, 14-month-old male SHR were treated for 48 hours
with esmolol (SHR-E, 300𝜇g/kg/min). Age-matched untreated male SHR andWistar Kyoto rats (WKY) were used as hypertensive
and normotensive controls, respectively. At the end of intervention we performed a histological study to analyze coronary artery
wall width (WW), wall-to-lumen ratio (W/L), and media cross-sectional area (MCSA). Dose-response curves for acetylcholine
(ACh) and sodiumnitroprussidewere constructed.We also assessed several plasma oxidative stress biomarkers, namely, superoxide
scavenging activity (SOSA), nitrites, and total antioxidant capacity (TAC).We observed a significant reduction inWW (𝑃 < 0.001),
W/L (𝑃 < 0.05), and MCSA (𝑃 < 0.01) and improved endothelium-dependent relaxation (AUCSHR-E = 201.2 ± 33 versus AUCSHR
= 97.5 ± 21, 𝑃 < 0.05) in SHR-E compared with untreated SHR; no differences were observed for WW, MCSA, and endothelium-
dependent relaxation by ACh at higher concentrations (10−6 to 10−4mol/l) for SHR-E with respect to WKY. SOSA (𝑃 < 0.001) and
nitrite (𝑃 < 0.01) values were significantly higher in SHR-E than in untreated SHR; however, TAC did not increase after treatment
with esmolol. Esmolol improves early coronary artery remodeling in SHR.
1. Introduction
The risk of fatal cardiovascular events is associated with
adverse structural and functional remodeling of the vascula-
ture, which is frequently caused by hypertension [1]. Regres-
sion of these changes is a goal of antihypertensive therapy [2]
and is associated with reduced incidence of cardiovascular
events [3, 4]. Chronic treatment with antihypertensive agents
(angiotensin-converting enzyme inhibitors, angiotensin II
receptor blockers, calcium antagonists, 𝛽-blockers, and
diuretics) has led to regression of vascular remodeling both
in humans and in animal models of hypertension [2, 5, 6].
However, early regression of coronary artery remodeling
after short-term therapy with these agents has not been
investigated.
Esmolol is an ultrashort-acting cardioselective 𝛽-
adrenergic blocker with a half-life of ∼2 minutes, a time to
peak effect of about 6–10 minutes, and a washout time of 9
minutes [7]. Therefore, esmolol is faster acting than other
𝛽-blockers and is an excellent option for the treatment of
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arterial hypertension and undesirable increases in heart rate
[8], although its effect on vascular remodeling has not been
established.
Our group previously demonstrated that short-term
treatment (48 hours) with esmolol reduces left ventricular
hypertrophy in spontaneously hypertensive rats (SHR) [9].
However, early changes in vascular remodeling and oxidative
stress following short-term use of this agent have not been
analyzed to date.
In the present study, we hypothesized that even short-
term administration (48 hours) of esmolol could reduce
structural and functional coronary artery remodeling by
increasing the bioavailability of nitric oxide (NO) and
superoxide dismutase activity (SOD) in SHR. Therefore, we
analyzed the protective effect of esmolol in coronary arteries
and antioxidant status in plasma.
2. Methods
All procedures conformed to the Guide for the Care and
Use of Laboratory Animals (NIH publication number 85-23,
revised in 1996) and Spanish legislation (RD 1201/2005) and
were approved by the Ethics Committee of Hospital General
Universitario Gregorio Maran˜on, Madrid, Spain.
2.1. Experimental Design. The study animals—14-month-old
male SHR (𝑛 = 22) and normotensive control Wistar-
Kyoto (WKY) rats (𝑛 = 11)—were bred at the animal
house of Universidad Auto´noma de Madrid. All the rats
were supplied with standard rat chow and drinking water
ad libitum and were maintained on a 12 h/12 h light/dark
cycle. The animals were housed at a constant temperature
of 24∘C and relative humidity of 40%. All the rats were
anesthetized with an intraperitoneal injection of diazepam
4mg/kg/1 and ketamine 10mg/kg/1, and a catheter was
inserted into the right internal jugular vein under sterile
conditions. SHRwere randomly divided into 2 groups (11 rats
each): rats treated with esmolol (SHR-E) and rats treated with
vehicle (SHR, hypertensive control group). SHR-E received
an intravenous infusion of esmolol at 300𝜇g/kg/min for 48
hours. SHR andWKY received saline solution (vehicle). After
48 hours of treatment, the rats were killed by decapitation.
Blood samples and the heart were removed immediately to
study oxidative stress and perform structural and vascular
reactivity experiments.
2.2. Blood Pressure and Heart Rate Measurements. Systolic
arterial pressure (SAP) and heart rate (HR) were measured
(conscious animals prewarmed to 35∘C in thermostatic cages)
by the tail-cuff method with a photoelectric sensor (Niprem
546, Cibertec, Madrid, Spain). Several determinations were
made and the findings were considered valid if 10 consecutive
measurements were within 10mmHg of each other.
2.3. Morphology of Intramyocardial Arteries. We analyzed 5
animals from each group. Left ventricular tissue was fixed
in 4% sodium-buffered formaldehyde. We made sequential
transversal cuts of the left ventricle from the subvalvular
region to the apex. Samples were then dehydrated and
embedded in paraffin. Serial sections (5𝜇m) were stained
with orcein. We differentiated between the subepicardial and
midmyocardial parts of the left ventricular wall, following the
procedure described by Lunkenheimer et al. [10]. We then
located the intramyocardial branch of the obtuse marginal
artery (branch of the circumflex coronary artery). A total of
30 intramyocardial arteries (2 vessels per rat) were observed
and analyzed using a high-resolution camera (Sony CCD
IRIS) attached to a microscope (Leica DMLB, ×40). The
morphometric analyses were performed using the method of
Gundersen el al. [11]. The images were projected on a com-
puter screen, and the external diameter (ED) (inner diameter
+ tunica intima + tunica media) and lumen diameter (LD) of
the coronary arteries were measured. The wall width (WW)
was expressed as (ED-LD)/2. The wall-to-lumen ratio (W/L)
was expressed as (WW/LD) × 100, and the media cross-
sectional area (MCSA) (tunica intima + tunica media) was
expressed as (𝜋/4) × (ED2−LD2) [6].
2.4. Blood Collection and Plasma Preparation. We analyzed
6 animals from each group. Blood (2.4mL) was collected
from each animal in Vacutainer tubes (BD, Plymouth, UK)
containing citrate (300 𝜇L). Blood samples were centrifuged
at 900 g for 10 minutes at 4∘C to obtain plasma, which was
aliquoted and stored at –80∘C for further analysis.
2.4.1. Nitrite. The plasma nitrite level was assessed using a
Griess reaction-based protocol adapted from Giustarini et
al. [12] and Miranda et al. [13]. One hundred microliters
of plasma or nitrite standard (0–100 𝜇M) was mixed with
10 𝜇L de N-ethylenediamine (150mM) to eliminate thiols
that interfere with the Griess reaction.Thereafter, the protein
from samples was precipitated by addition of 110 𝜇L of
trichloroacetic acid (20% w/v) and incubation in an ice bath
for 5 minutes. Fifty microliters of supernatant obtained by
centrifugation at 12,000 g for 5 minutes (4∘C) was mixed
on 96-well plate with 50𝜇L of saturated vanadium chloride
(dissolved in HCl 1M), 25𝜇L of sulphanilamide (2% w/v in
HCl 5%v/v), and 25 𝜇LofN-naphthyl-ethylenediamine (0.1%
w/v in water). Finally, the mixture was incubated at 37∘C for 1
hour, and the absorbance was read at 540 nm. Plasma nitrite
content was expressed in 𝜇M.
2.4.2. Quantification of Superoxide Scavenging Activity
(SOSA). Plasma superoxide anion scavenging activity was
assessed using the SOSA assay based on the inhibition of
luminescence emitted by coelenterazine, which is oxidized
by superoxide anion [14]. Superoxide anion was produced
using a hypoxanthine/xanthine oxidase system. SOSA values
were quantified by comparing the luminescence inhibition of
each sample with that observed on the superoxide dismutase
activity standard curve (0–4mU/mL) and expressed as
mU/mL.
2.4.3. Catalase Activity. Catalase activity was assessed using
the Amplex red catalase assay (Catalase Assay Kit with
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Amplex Ultra Red reagent; Invitrogen). Catalase activity was
expressed as units per milligram of protein.
2.4.4. Total Antioxidant Capacity (TAC). TAC was assessed
using a modified CUPRAC-BCS assay. Briefly, 10 𝜇L of
diluted plasma with phosphate buffer (10mM, pH = 7.4)
was mixed on 96-well plate with 190𝜇L of BCS 0.25mM
(dissolved in phosphate buffer), and the initial absorbance
(Ai) was measured at 490 nm. Thereafter, 50𝜇L of CuSO
4
(0.5mM dissolved in water) was added, the mix was incu-
bated in darkness at room temperature for 5 minutes, and
the final absorbance (Af) was measured at 490 nm. TAC was
calculated from (Af-Ai) and the standard curve and expressed
as mM Trolox.
2.4.5. Total Thiols. Plasma thiols were assessed using the
microplate 5,5󸀠-dithiobis (2-nitrobenzoic acid) assay [15].The
absorbance was measured at 412 nm in a Synergy HT Multi-
Mode Microplate Reader (BioTek, Potton, UK), and thiol
content was expressed as millimoles per liter of reduced
glutathione per milligram of protein.
2.4.6. Protein Content. Protein content was assessed using
a Coomassie blue-based microtiter plate assay with bovine
serum albumin as standard (Bio-Rad). The absorbance was
measured at 595 nm in a Synergy HTMulti-ModeMicroplate
Reader.
2.5. Vascular Reactivity of Coronary Arteries. We analyzed
6 animals from each group. The heart was removed and
maintained in cold (4∘C) oxygenated Krebs-Henseleit solu-
tion (KHS, in mmol⋅L−1: 115 NaCl, 25 NaHCO
3
, 4.7 KCl,
1.2 MgSO
4
⋅7H
2
O, 2.5 CaCl
2
, 1.2 KH
2
PO
4
, 11.1 glucose, and
0.01 Na
2
EDTA). Segments of the left anterior descending
artery were isolated, and surrounding cardiac tissue was
cleaned under a dissecting microscope. Segments of coro-
nary arteries (2mm in length) were mounted on a wire
myograph (Multi Myograph System, model 610M; Danish
Myo-Technology) coupled to a Powerlab data acquisition
system (AD-Instruments, Castle Hill, Australia) and studied
as described elsewhere [16]. Briefly, the vessel wasmounted in
oxygenated KHS. The arteries were then set to a normalized
internal circumference of 0.9 L100, which was considered as
the effective lumen diameter that represented the basal tone
of the artery. After an equilibration period in KHS at 37∘C
and pH 7.4, segments were stretched to their optimal lumen
diameter to develop active tension. Coronary arteries were
exposed to 120mmol⋅L−1K+-KHS in order to ensure their
functional integrity. Responses to acetylcholine (ACh, 10−9
to 10−4mol/l) were studied in segments precontracted with
5-hydroxytryptamine (5-HT, 3 × 10−7mol/l). After a washout
period of 60minutes, dose-response curves were constructed
for sodium nitroprusside (SNP, 10−9 to 10−4mol/l) to study
endothelium-independent relaxation in segments precon-
tracted with 5-HT (3 × 10−7mol/l).
2.6. Data Analysis and Statistics. The results were expressed
as mean ± SEM. Between-group comparisons were made
by 1-way analysis of variance followed by a Bonferroni post
hoc test. Relaxing responses are expressed as percentage
reduction in the 5-HT preconstricted state. To compare the
effect of vasodilator drugs on response to 5-HT in coronary
segments, some results were expressed as differences in the
area under the concentration-response curves between the 3
experimental groups. 𝑃 < 0.05 was considered statistically
significant. The statistical analysis was performed using SPSS
17.0 for windows (SPSS, Chicago, Illinois, USA) and S-PLUS
6.1.
3. Results
3.1. Physiological Parameters. Body weight was higher in
WKY than in SHR (441.60 ± 22.08 g versus 405.13 ± 22.12 g,
𝑃 < 0.05) and SHR-E (441.60±22.08 g versus 400.15±11.07 g,
𝑃 < 0.05). Heart weight was higher in SHR than in WKY
(2.10±0.27 g versus 1.51±0.11 g,𝑃 < 0.05) but decreased after
treatment in SHR-E compared with SHR (1.49±0.12 g versus
2.10 ± 0.27 g, 𝑃 < 0.05). There were no significant differences
in heart weigh between SHR-E and WKY.
3.2. Hemodynamic Parameters. SAP was higher in SHR than
inWKY (236±1.5 versus 135±0.1,𝑃 < 0.001). After 48 hours
of treatment, esmolol lowered SAP in SHR-E with respect to
SHR (149±2 versus 236±1.5, 𝑃 < 0.001), and the SAP values
at the end of treatment were not comparable with those of
theWKY (𝑃 < 0.05). Heart rate remained unchanged in both
SHR and WKY (297 ± 1 versus 297 ± 2) but decreased after
treatment in SHR-E comparedwith SHR (183±3 versus 297±
1, 𝑃 < 0.001) and WKY (𝑃 < 0.001).
3.3. Effect of Esmolol on Intramyocardial Artery Morphology.
Intramyocardial artery ED was significantly greater in SHR
than inWKY. Administration of esmolol to SHR-E decreased
ED, although the difference was not statistically significant
compared with untreated SHR (Figures 1(a) and 2). The
LD of the artery in SHR was significantly greater than in
WKY. Administration of esmolol increased LD by a greater
amount in SHR-E than in SHR, although the difference was
not statistically significant (Figures 1(b) and 2). The WW
of the artery was significantly higher in SHR than in WKY.
Interestingly, WW was significantly lower after 48 hours of
treatment in SHR-E than in SHR, although no differences
were detected with respect to WKY (Figures 1(c) and 2).
The W/L in SHR did not differ from that in the WKY.
Administration of esmolol significantly decreased the W/L
ratio in SHR-E (Figures 1(d) and 2). The MCSA in the
SHR was larger than in the WKY. Interestingly, MCSA was
significantly lower after 48 hours of treatment in SHR-E than
in SHR; no differences were observed with respect to WKY
(Figures 1(e) and 2).
3.4. Effect of Esmolol on Coronary Artery Vasodilator Func-
tion. In WKY and SHR-E rats, ACh elicited concentration-
dependent relaxation at all the concentrations tested, whereas
in SHR, ACh elicited a biphasic response with dilatation
at low concentrations (10−9 to 10−5mol/l) and contractions
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Figure 1: Structural parameters. (a) External diameter, (b) lumen diameter, (c) wall thickness, (d) wall-to-lumen ratio, and (e) media cross-
sectional area of intramyocardial artery of the left ventricle fromWistar Kyoto control rats (WKY, 𝑛 = 5), spontaneously hypertensive control
rats (SHR, 𝑛 = 5), and spontaneously hypertensive rats treated with esmolol (SHR-E, 𝑛 = 5). Data are expressed as mean ±SEM. Statistically
significant differences between WKY, SHR, and SHR-E are shown ( ∗𝑃 < 0.05 versus WKY; ∗∗𝑃 < 0.01 versus WKY; ∗∗∗𝑃 < 0.001 versus
WKY; #𝑃 < 0.05 versus SHR; ##𝑃 < 0.01 versus SHR; ###𝑃 < 0.001 versus SHR).
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Figure 2: Examples of histological sections of the intramyocardial artery of the left ventricle from a Wistar Kyoto control rat (WKY),
spontaneously hypertensive control rat (SHR), and spontaneously hypertensive rat treated with esmolol (SHR-E). Orcein x10.
at higher concentrations (10−4mol/l). The endothelium-
dependent relaxation induced by ACh in 5-HT contracted
coronary arterieswas significantly lower in SHR than inWKY
(10−7 to 10−4mol/l), and esmolol significantly improved this
relaxation (10−6 to 10−4). Treatment with esmolol normalized
coronary artery endothelium-dependent relaxation by ACh
at higher concentrations (10−6 to 10−4mol/l) (Figure 3(a)).The
AUCwas significantly larger inWKY than in SHR (AUCWKY
= 265.9 ± 27 versus AUCSHR = 97.5 ± 21, 𝑃 = 0.0002). AUC
was significantly higher in SHR-E than in SHR (AUCSHR-E
= 201.2 ± 33 versus AUCSHR = 97.5 ± 21, 𝑃 = 0.027); no
differences were observed for SHR-E with respect to WKY.
No differences in the concentration-response curves
for the endothelium-independent vasodilator SNP (10−9 to
10−4mol/l) were observed between the 3 experimental groups
(AUCWKY = 292.9 ± 34; AUCSHR = 253.2 ± 19; AUCSHR-E
= 307.2 ± 34) (Figure 3(b)). Maximal dilatation to SNP was
97.7±1% inWKY, 91.4±2% in SHR, and 98.6±1% in SHR-E
(Figure 3(b)).
3.5. Effect of Esmolol on NO Level and Plasma Antioxidant
Status. Interestingly, plasma nitrite level was significantly
higher after 48 hours of treatment in SHR-E than in SHR
(Figure 4(a)). No differences were observed between SHR
and WKY, although a trend toward reduction was recorded
(Figure 4(a)). Moreover, the SOSA value, which is in part
related to superoxide dismutase activity, was significantly
increased after treatmentwith esmolol in SHR-E, although no
differences were observed for this enzyme in SHR compared
withWKY (Figure 4(b)). Similarly, administration of esmolol
increased catalase activity in SHR-E but not in SHR or
WKY (Figure 4(c)). Finally, administration of esmolol did not
change total plasma antioxidant activity (Figure 4(d)) or thiol
level (Figure 4(e)) in SHR-E, SHR, or WKY.
4. Discussion
Our results show that short-term (48 hours) intravenous
infusion of esmolol (300 𝜇g/kg/min) in adult SHR induces
early changes of coronary artery remodeling by increased
bioavailability of NO and improved antioxidant status in
plasma.This is the first study to show an association between
early improvement in coronary artery remodeling with
short-term administration of a 𝛽-blocker. Although previous
human and experimental animal studies have demonstrated
that various antihypertensive drugs can reverse coronary
artery remodeling, they have all been conducted with drugs
administered over several months [17–22].
4.1. Effect of Esmolol on Vascular Structure and Function.
Hypertension is associated with structural and functional
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Figure 3: Vascular reactivity parameters. (a) acetylcholine (ACh) responses and (b) sodium nitroprusside (SNP) in left anterior descending
artery precontracted with 5-hydroxytryptamine (5-HT, 3 × 10−7mol/l) from Wistar Kyoto control rats (WKY, 𝑛 = 6), spontaneously
hypertensive control rats (SHR, 𝑛 = 6), and spontaneously hypertensive rat treated with esmolol (SHR-E, 𝑛 = 6). Relaxing responses are
expressed as percentage reduction in the 5-HT preconstricted state. Data are expressed as mean ± SEM. Statistically significant differences
between WKY, SHR, and SHR-E are shown ( ∗∗𝑃 < 0.01 versus WKY; ∗∗∗𝑃 < 0.001 versus WKY; #𝑃 < 0.05 versus SHR).
changes in vascular remodeling, which in turn increase car-
diovascular risk [23]. In our experiments, we found thatWW,
MCSA, and LD of intramyocardial arteries in 14-month-old
SHRwere higher than inWKY.These data are consistent with
those of Cebova and Kristek [24], who reported remodeling
in the septal branch of the descending coronary artery in 13-
month-old SHR; however, the authors found no differences
in young SHR and age-matched WKY. The gradual increase
in all 3 parameters (WW, MCSA, and LD) with age in
coronary artery hypertrophy in SHR could reflect an adaptive
mechanism triggered by chronic arterial hypertension.
At 14 months of age, SHR present compensated left
ventricular hypertrophy (LVH) [25], which is associated with
functional and structural alterations of the coronary artery
[26]. We previously reported that 48-hour treatment of SHR
with esmolol produces regression of LVH [9], and the results
of the present study suggest that coronary artery WW and
MCSA in SHR normalizes to those of WKY after treatment.
These data are consistent with the effect of other antihy-
pertensive agents (losartan [17], perindopril [18], amlodipine
and enalapril [19], indapamide [20], and carvedilol [22]) in
coronary artery remodeling, although only after long-term
treatment. Regression of vascular remodeling is difficult, even
with long-term pharmacological treatment [27], although
esmolol produced changes in vascular structure and function
in 48 hours. This effect may be attributed in part to the
fact that short-term intravenous administration of esmolol
exerts a greater hypotensive effect than other drugs [28].
We do not know whether esmolol plays a role in fibrosis,
hypertrophy, or both in the coronary arteries. However, in a
previous study [9], we showed that esmolol (300𝜇g/kg/min
for 48 h) produces early changes in cross-sectional area of left
ventricular cardiomyocytes (in subepicardial region) in SHR
but does not affect collagen volume fraction.
Our results show hypertrophic outward remodeling
(associated with an increase in arterial wall mass and lumen
thickness) [1] in intramyocardial arteries in 14-month-old
SHR. However, esmolol produced eutrophic outward remod-
eling (decreases in wall thickness to inner diameter ratio),
which is associated with a decrease in vascular resistance and,
consequently, a decrease in arterial pressure [29].
4.2. Effect of Esmolol on Plasma Antioxidant Parameters.
Esmolol is an ultrashort-acting specific blocker of 𝛽1-
adrenergic receptors with an elimination half-life of 9 min-
utes [30]; in other words, recovery from 𝛽 blockade (i.e.,
heart rate approaching baseline levels) can be achievedwithin
10 minutes of discontinuing the infusion [31]. We recently
demonstrated that short-term treatment with esmolol can
reverse early left ventricular hypertrophy in the SHR model
of stable compensated ventricular hypertrophy [9], although
the underlying mechanism has not been explored. The level
of plasma nitrite in SHR-Ewas significantly higher than in the
SHR and WKY groups. Nevertheless, a similar improvement
has been reported for other blockers of 𝛽-adrenergic recep-
tors, such as nebivolol [32], carvedilol [33], and nipradilol
[34]. The increase in plasma NO level after administration of
esmolol to SHRwasmarkedly greater thanwith𝛽1-adrenergic
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Figure 4: Antioxidant parameters. (a) Nitrites, (b) superoxide scavenging activity (SOSA), (c) catalase, (d) total antioxidant capacity (TAC),
and (e) thiols on plasma from Wistar Kyoto control rats (WKY, 𝑛 = 6), spontaneously hypertensive control rats (SHR, 𝑛 = 6), and
spontaneously hypertensive rat treated with esmolol (SHR-E, 𝑛 = 6). Data are expressed as mean ± SEM. Statistically significant differences
between WKY, SHR, and SHR-E are shown ( ∗𝑃 < 0.05 versus WKY; ∗∗𝑃 < 0.01 versus WKY; ∗∗∗𝑃 < 0.001 versus WKY; ##𝑃 < 0.01 versus
SHR; ###𝑃 < 0.001 versus SHR).
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receptor blockers, even in WKY [32]. On the other hand,
the reduced asymmetric dimethylarginine (ADMA) concen-
tration in SHR treated with nebivolol, a third-generation 𝛽-
blocker, has been associated with endothelial NO synthase
(eNOS) agonist properties and increased bioavailability of
NO [32]. In addition, ADMA has been shown to increase
ROS level in arterioles in vitro by activation of the vascular
renin-angiotensin system [35]. In our study, we showed
that SOSA, which includes low-molecular weight antioxidant
(scavengers) and superoxide dismutase, increased as a result
of treatment with esmolol. The fact that total antioxidant
activity does not increase after treatmentwith esmolol reflects
an increase in superoxide dismutase activity measured using
the SOSA assay. Likewise, catalase activity was also increased
by esmolol in SHR. Esmolol does not exert its antioxidant
activity through ROS-scavenging mechanisms [33] similar
to those found in this study, and total antioxidant activity
did not change with esmolol, although plasma superoxide
dismutase activity and catalase activity can be induced by
esmolol. This explains how the increase in plasma NO level
in SHR after treatment with esmolol was markedly greater
than with other 𝛽-blockers. Based on these results, esmolol
can improve the oxidative stress associated with arterial
hypertension. Antioxidant capacity is one of the mechanisms
that underlie the efficacy of antihypertensive therapy [36].
Esmolol increases nitric oxide bioavailability and super-
oxide dismutase activity. These effects could explain struc-
tural changes and attenuation of coronary artery dysfunction.
However, the vascular remodeling (structural changes) in
hypertension is also associated with activation of the renin-
angiotensin system, endothelin-1, endothelial dysfunction,
oxidative stress, and ADMA [37].
4.3. Study Limitations. This study was designed to analyze
the effect of esmolol on the structure and function of the
coronary arteries. Although esmolol produces changes in
coronary artery structure and function, we cannot conclude
that regression of vascular remodeling occurred, because we
did not study aspects such as markers of smooth muscle pro-
liferation, activity of matrix metalloproteinases, and staining
of perivascular fibrosis. Future studies will be necessary to
answer this question.
In conclusion, our results show that esmolol improves
coronary artery remodeling by increasing bioavailability of
NO and improving antioxidant status in plasma in SHR,
because lower WW and lower MCSA, improved endothelial
dysfunction, and increased plasma NO level and superoxide
dismutase activity were observed in SHR-E compared with
the control SHR. Ours is the first study to show improvement
of coronary artery remodeling with a 𝛽-blocker in the short
term. If these results are confirmed in humans, esmolol could
be taken into consideration for the treatment of patients with
coronary artery disorders caused by arterial hypertension.
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